The agency issued a Form 483 with 6 observations for Drug Substance, Drug Product units and Quality Control laboratories
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
The agreement extends the customer's suite of cloud DevOps, data engineering, and data platform management solutions
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The launch of HULIO in the United States is an important milestone for Biocon Biologics
Subscribe To Our Newsletter & Stay Updated
